Opinion|Videos|January 23, 2025 (Updated: January 23, 2025)
Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
Author(s)Misako Nagasaka, MD, PhD
Panelist discusses how the DESTINY-Lung02 trial was a dose optimization study where patients with HER2-mutated non–small cell lung cancer (NSCLC) were randomly assigned to a starting dose of 5.4 mg/kg vs 6.4 mg/kg of trastuzumab deruxtecan (T-DXd). DESTINY-Lung03 was a frontline study for HER2 overexpression in NSCLC looking at different combinations of treatment with T-DXd and immunotherapy agents with or without chemotherapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Review updates and discuss the clinical implications from the following trials:
- DESTINY-Lung02 (Janne PA. 2024 American Society of Clinical Oncology Annual Meeting. Abstract 8543)
- DESTINY-Lung03 part 1 (Planchard D. World Conference on Lung Cancer 2024. Abstract 730)
- Please highlight any other trials of note in NSCLC and share your approach to clinical decision-making.
Advertisement
Related to this article
Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.
The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.
Partnering with subspecialities like ophthalmology and dermatology may be critical for nurse practitioners in lung cancer, according to Beth Sandy, CRNP.
Beth Sandy, CRNP, said she would like to see more data on management strategies for blepharitis, eye toxicities, and mucositis in patients with lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
3
Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy
4
PALOMA-2 Shows Improved Survival vs Historical IV Amivantamab Data
5